CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
树突状细胞疫苗治疗胶质母细胞瘤未能完成临床转化：瓶颈与潜在对策
英文原题：Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential countermeasures.
查看英文原题
Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential countermeasures.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质母细胞瘤（GBM）是一种异质性、侵袭性的WHO IV级脑肿瘤。接受手术切除和放化疗的GBM患者中位总生存期（OS）仅为14至17个月。作为最有前景的抗肿瘤免疫疗法之一，树突状细胞（DC）疫苗已在许多临床试验中展现出良好的疗效、安全性和耐受性。然而，迄今为止，尚无III期临床试验取得阳性终点并真正实现临床开发与转化。此外，DC疫苗对GBM患者的生存获益似乎具有延迟效应；因此，我们迫切需要优化DC疫苗的策略，以提前其生存获益的时间点。在此，我们讨论DC疫苗在GBM中的最新临床试验进展，并总结各种疫苗设计方案的优缺点，以及临床转化中面临的挑战。此外，我们针对DC疫苗在GBM中的未来联合治疗策略进行探讨，为全面理解DC疫苗开发的有效性、局限性及新方向提供了新视角。
展开英文摘要原文
Glioblastoma (GBM) is a heterogeneous and invasive WHO grade IV brain tumor. Patients with GBM have a median overall survival (OS) of only 14 to 17 months when treated with surgical resection and chemoradiation. As one of the most promising anti-tumor immunotherapies, dendritic cell (DC) vaccines have demonstrated good efficacy, safety, and tolerability in many clinical trials.
However, to date, no Phase III clinical trial has achieved positive endpoints and truly implement clinical development and transformation.
Moreover, the survival benefits of DC vaccines for patients with GBM seem to have a delayed effect; therefore, we urgently require strategies to optimize DC vaccines to advance the time point of its survival benefits.
Here, we discuss the latest clinical trial progress of DC vaccines in GBM and summarize the benefits and drawbacks of various vaccine design options, as well as the challenges faced in clinical translation.
Moreover, we target future combination therapy strategies for DC vaccines in GBM, which provides a new perspective for comprehensively understanding the effectiveness, limitations, and new directions of the development of DC vaccines.
论文信息
- 作者
- Li L、Zhou J、Dong X、Liao Q、Zhou D、Zhou Y
- 第一作者单位
- NHC Key Laboratory of Carcinogenesis, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China; Cancer Research Institute, Basic School of Medicine, Central South University, Changsha, Hunan 410078, China; Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.China
- 通讯作者单位
- NHC Key Laboratory of Carcinogenesis, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China; Cancer Research Institute, Basic School of Medicine, Central South University, Changsha, Hunan 410078, China; Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China. Electronic address: zhouyanhong@csu.edu.cn.China
- 文献类型
- 综述
- 期刊
- International immunopharmacology2022 Aug
- 原文标识
- PubMed 35700581 · DOI 10.1016/j.intimp.2022.108929